Endiatx, a technology company, has developed a new piece of equipment called PillBots that are undergoing clinical trials in the hopes of receiving FDA review. If successful, these small robots could potentially be launched commercially as early as 2026. The PillBots are swallowable robots that come equipped with cameras and sensors which allow them to perform non-invasive endoscopies without the need for traditional upper endoscopies (EGD).
These robots provide doctors with a quick look inside the stomach during telemedicine calls, making it easier to navigate internal affairs without sedation or extensive fasting from the patient. After being ingested, the PillBot moves around the body using patented multi-pumpjet propulsion controlled remotely by doctors. The live feed from inside the body, illuminated by the robot’s LED system, is saved for later AI-enhanced analysis.
Endiatx CEO Torrey Smith has demonstrated the process multiple times by swallowing the PillBot himself. The robot shuts off and passes through the gastrointestinal system within 24 hours of ingestion. The company has raised $7 million in funding and is working on improving video quality that can be transmitted by the PillBot.
PillBots are expected to be affordable and could potentially be purchased over-the-counter at around $50 per unit. Endiatx is also considering expanding their product line with PillSurgeon, a version of the PillBot equipped with tools for tasks such as removing polyps, collecting microbiome samples, cauterizing bleeds, and performing biopsies.
